SUMMARY The role of plasma angiotensin II (Ang II) in furosemide-stimulated renal prostaglandin Ej (PGEj) production was evaluated in eight healthy subjects. Urine was collected for 60 minutes after forosemide administration (20 mg i.v.) with or without captopril pretreatment, and urinary excretion of PGE 2 , sodium, and furosemide was determined. Plasma renin activity (PRA) and Ang II were also measured before and 60 minutes after furosemide administration. Urinary PGEj excretion, PRA, and Ang II increased after furosemide administration without captopril pretreatment, and there was a significant correlation between the increment in Ang II and that in urinary PGE 2 excretion. Urinary PGE 2 excretion and Ang II did not increase after furosemide administration with captopril pretreatment. Urine volume and urinary excretion of sodium and furosemide were not influenced by captopril pretreatment. These results suggest that Ang II may play an important role in furosemide-stimulated PGE 2 production. (Hypertension 11: 491-494, 1988) KEY WORDS • furosemide • prostaglandin E 2 • angiotensin II F UROSEMIDE, a potent loop diuretic, is a widely used therapeutic agent for treatment of hypertension and congestive heart failure. Some effects of furosemide are reported to be partly dependent on renal prostaglandin E2 (PGE2) produced by furosemide administration. 12 This elevation in renal PGEj production, as reflected by urinary PGEj excretion, 3 following furosemide administration could be mediated directly by inhibition of renal 15-hydroxyprostaglandin dehydrogenase 4 and 9-ketoreductase 5 activities. Since furosemide activates the renin-angiotensin system, the elevated levels of angiotensin II (Ang II) may in turn stimulate synthesis of renal PG1V To determine whether the indirect action of Ang II plays an important role in furosemide-induced renal PGE2 production, we investigated urinary PGE2 excretion after furosemide administration with or without pretreatment with captopril, an oral converting enzyme inhibitor, in healthy subjects.
F UROSEMIDE, a potent loop diuretic, is a widely used therapeutic agent for treatment of hypertension and congestive heart failure. Some effects of furosemide are reported to be partly dependent on renal prostaglandin E2 (PGE2) produced by furosemide administration. 12 This elevation in renal PGEj production, as reflected by urinary PGEj excretion, 3 following furosemide administration could be mediated directly by inhibition of renal 15-hydroxyprostaglandin dehydrogenase 4 and 9-ketoreductase 5 activities. Since furosemide activates the renin-angiotensin system, the elevated levels of angiotensin II (Ang II) may in turn stimulate synthesis of renal PG1V To determine whether the indirect action of Ang II plays an important role in furosemide-induced renal PGE2 production, we investigated urinary PGE2 excretion after furosemide administration with or without pretreatment with captopril, an oral converting enzyme inhibitor, in healthy subjects. three separate occasions. The subjects were requested to refrain from sexual activity and not to take nonsteroidal anti-inflammatory drugs for at least 48 hours before the study. Sodium intake was not restricted until the night before the study. Urine was collected for 24 hours on the day before each study. After fasting overnight, subjects were given 400 ml of water to drink at 0900, 1030, 1200, and 1300 and were asked to void at 1300. The subjects remained supine throughout the study except for 1 to 2 minutes of standing to pass urine. In the first study, urine was collected for 60 minutes after administration of vehicle (10 ml of saline) at 1300. In the second study, 10 ml of saline containing 20 mg of furosemide was injected intravenously after voiding urine at 1300. Urine was collected for 60 minutes after furosemide administration. Blood samples were obtained before and 60 minutes after furosemide administration. In the third study, the procedure of the second study was repeated but a blood sample was also obtained and 50 mg of captopril was given orally at 1200. These three studies were performed at 7-day intervals.
Analytical Procedures
Blood samples for measurement of plasma renin activity (PRA) and Ang II were collected into tubes containing EDTA and kept on ice. After centrifugation at 2000 g at 4°C for 20 minutes, the plasma was separated. Plasma and urine samples were immediately frozen and stored at -20 °C in a freezer that had no cyclic system for defrosting and were analyzed within 2 weeks. PRA 7 and Ang n 8 were measured by radioimmunoassay. Urinary sodium was determined by a flame photometer (Model 775-A, Hitachi, Tokyo, Japan). Urinary furosemide was measured using high performance liquid chromatography. 9 Urinary PGEj was measured by radioimmunoassay after extraction according to the method of Jaffe et al. 10 with a slight modification. In brief, after 0.2 N hydrochloric acid was added to 1 ml of urine to adjust to a pH of 3 to 5, the sample was defatted with 3 ml of n-hexane to which 3 ml of acetic acid and ethylisopropanol (1:1, vol/vol) mixture was added and mixed well, then the organic layer was separated with 5 ml of ethylacetic acid and water (2:3, vol/vol) mixture. The upper layer was evaporated, and the residue dissolved with a 1-ml mixture of benzene, ethyl acetate, and methanol (60:40:2, vol/vol/vol). The extract was then applied onto the minicolumn (8 X 160 mm) packed with 1.5 g of silicic acid, and the fraction of PGE2 was collected. The recovery rate of PGEi was 85.0 ± 5.0% (n = 7). PGEj was not converted to prostaglandin A, in this extraction procedure. PGE2 was measured by radioimmunoassay using a kit (Clinical Assays, Travenol, Deerfield, IL, USA) after conversion to prostaglandin B (PGB) by treating with 0.1 ml of 1 N sodium hydroxide and heating at 100°C for 5 minutes. Greater than 90% of PGE2 was converted in the alkalinizing process to PGB. The cross-reactivity of anti-PGB antibody was 100% with PGB, 22.2% with prostaglandin A,, less than 0.1% with prostaglandin A 2 , 12.3% with prostaglandin E 1; less than 0.1% with PGE2, less than 0.1% prostaglandin F, a (PGF,,,), and less than 0.1% prostaglandin F^. Tritium-labeled PGE2 (1000 cpm) was added to the urine for correction of the recovery rate. The sensitivity of this assay was 20 pg/ml of urine, and the intra-assay and interassay coefficients of variation were 10% (x = 48 pg/ml; n = 15) and 15% (x = 48 pg/ml; n = 15), respectively. Urinary captopril did not interfere with this assay. tween the increment in Ang II and that of urinary PGE? after furosemide administration without captopril pretreatment ( Figure 1 ). Urine volume and urinary excretion of sodium and furosemide after furosemide administration were not influenced by captopril pretreatment (see Table 1 ). There were significant correlations between urinary
Statistical Analysis
The results obtained are expressed as means ± SE. Data are analyzed by analysis of variance.
Results
There were no significant differences among the three studies in urinary sodium excretion (170-200 mEq/24 hr) on the day before the study. There was a significant increase in urinary PGE^ excretion after furosemide administration (Table 1) . This increase disappeared with captopril pretreatment.
After furosemide administration alone, both PRA and Ang II increased (Table 2 ). Captopril pretreatment in the third study increased basal PRA from 1.1 ±0.3 to 7.1 ± 2.3 ng angiotensin I/ml/hr (/><0.05) and decreased basal Ang II from 12.6 ± 1.9 to 8.1 ± 1.1 pg/ml (p<0.05). Following captopril pretreatment, furosemide produced a greater increase in PRA but produced no significant change in Ang II (see Table 2 ). There was a high correlation (r = 0.78, p<0.05) be- furosemide excretion and the increment in urine volume {n = 16, r = 0.56, p < 0 . 0 5 ) and in urinary sodium excretion (n = 16, r = 0.55, p < 0 . 0 5 ) . However, there was no significant correlation between the increment in urinary PGEj excretion and that in urine volume or urinary sodium excretion after furosemide administration without captopril pretreatment.
Discussion
The present study demonstrates that urinary PGEj excretion increases significantly after furosemide administration and this increment is completely inhibited by captopril pretreatment. The present study also reveals a high degree of correlation between changes in plasma Ang II concentration and in urinary PGEj excretion during the study without captopril pretreatment. These observations confirm and extend a previous report by Attallah et al. , 6 who suggested that the effect of furosemide on renal PGE2 production is mediated through the action of Ang n. Ang II is reported to stimulate PGE2 synthesis in the kidney," in cultures of renal medullary interstitial cells, 12 and in isolated glomeruli. 13 On the basis of these observations, the observed increment in furosemide-induced renal PGE2 production can be entirely accounted for by the concurrent increase in Ang n . The obliteration of this response by captopril pretreatment provides additional support for this thesis. For these reasons, the effect of furosemide on the prostaglandin degrading enzymes appears negligible.
Furosemide increases urinary excretion of several prostaglandins, including PGEj 14 and 6-keto-PGF la 15 in humans. Ang II stimulates arachidonic acid release through Ang II-activated phospholipase A 2 and subsequent prostaglandin biosynthesis. 3 ' n Ang n has been shown to stimulate PGE2 and 6-keto-PGF la production by isolated human glomeruli. 13 Therefore, the increase in urinary 6-keto-PGF, a after furosemide administration also might be decreased by captopril, although this was not examined in the present study.
As the urinary PGE2 excretion after captopril alone was not determined in the present study, a direct effect of the drug on urinary PGE2 excretion could not be evaluated. However, since captopril is reported to increase plasma levels of PGEj, 16 ' " it is not likely that captopril prevents the increment in urinary PGEj excretion after furosemide administration by a mechanism other than inhibition of its furosemide-related effect.
The contribution of renal PGE? to the mechanism of action of furosemide is still debated. After furosemide was administered intravenously, urinary PGE2 increased rapidly during the first 15 to 30 minutes' 118 and this increase was related to natriuresis in two studies, 1 -" but not in a third." In the present study, the urine volume and urinary sodium excretion responses to furosemide administration were not influenced by captopril pretreatment, although urinary PGEj excretion was remarkably reduced. Moreover, there were no significant correlations between the increment in urinary PGEj and that in urine volume or urinary sodium excretion after furosemide administration without captopril pretreatment. Our results agree with the work of Nadler et al., 20 which demonstrated that Ang II by itself stimulates PGE2 excretion without affecting urine volume and urinary sodium excretion. Therefore, it may be concluded from the present study that renal PGE2 does not play an important role in the diuretic and natriuretic effects of furosemide. The benefit of antianginal protection plus safety. . . .
CARDIZEM A FULLER UFE diltiazem HCI/Marion

16
il remarkable safety profile
The low incidence of side effects wifh Cardizem allows patients to feel better
Protection against angina attacks'*"
The predictable efficacy of Cardizem in stable exertional* and vasospastic angina allows patients to do more.
A decrease In myocardlal oxygen demand
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VASOTEC (ENALAPRIL MALEATE MSD)
Certain CNS effects, such as impairment of memory, nightmares, or depression, have not been characteristic of VASOTEC.
Little or No interference with Physical or Mental Activity
Certain subjective symptoms such as malaise and drowsiness, which may interfere with physical or mental activity, have not been characteristic of VASOTEC-a fact that may be related to the specificity of action of VASOTEC on the renin-angiotensinaldosterone system. VASOTEC Is contraindicated in patients who are hypersensitive to this product. Angioedema of the face, extremities, lips, tongue, glottis, and/or larynx has been reported in patients treated with angiotensinconverting-enzyme (ACE) inhibitors, including VASOTEC (0.2% of patients treated with VASOTEC in clinical trials). In such cases, VASOTEC should be promptly discontinued and the patient carefully observed until the swelling disappears Angioedema associated with laryngeal edema may be fatal Where there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL), should be promptly administered. 
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Contraindications: VASOTEC* (Enatapril Mateale, MSD) is corrtraindicated in patients who are hypersensitive to this product Warning*: Angioedema Angioedema of the tace, extremities, lips, tongue, glottis, and/or larynx has been reported in patients treated with ACE inhibitors, including VASOTEC In such cases, VASOTEC should be promptly discontinued and the patient carefully observed until the swelling disappears In instances where swelling has been confined to the tace and lips, the condition has generally resolved without treatment, although antihislamines have been useful in relieving symptoms Angioedema associated with laryngeal edema may be tatal Where there is Invotvernent of the tongue, glottis, of larynx, likely to crass alrwiy obstruction, appropriate therapy, e.g., subcutaneous eplnephrine solution 11000 (0.3 mL to 0.5 mL), should be promptly administered. (See ADVERSE REACTIONS) Hypotension Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence ol enalapfil use in severely salt/volume-depleted persons such as those treated vigorously with diuretics or patients on dialysis (See PRECAUTIONS. Drug Interactions and ADVERSE REACTIONS) In patients with severe congestive heart failure, with or without associated renal insufficiency, excessive hypotension has been observed and may be associated with oligurta and/or progressive azotemia, and rarely with acute renal failure and/or death Because ot the potential fall in blood pressure in these patients, therapy should be started under very close medical supervision Such patients should be followed dosefy for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in wtiom an excessive tall in blood pressure could result in a myocardial infarction or cerebrovascular accident If hypotension occurs, the patient should be placed in supine position and, if necessary receive an intravenous infusion of normal saline A transient hypotensrve response is not a contraindication to further doses, which usually can be given without difficulty once ttie blood pressure has increased after volume expansion NeutropenialAgranulocytosis Another ACE inhibitor has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially it they also have a collagen vascular disease Available data Irom clinical trials of enalapril are insufficient to show tfiat enalapril does not cause agranulocytosis at similar rates Foreign marketing experience has revealed several cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded Periodic monitoring ol white blood cell counts in patients with collagen vascular disease and renal disease should be considered Precautions: Genera/ Impaired Renal Function As a consequence of inhibiting the renm-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals In patients with severe congestive heart failure whose renal function may depend on the activity ot the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including VASOTEC. may be associated with oliguna and/or progressive azotemia and rarely with acute renal failure and/or death In clinical studies in hypertensive patients with unilateral or bilateral renal arlery stenosis, increases in blood urea nitrogen and serum creatimne were observed in 20% ot patients These increases were almost always reversible upon discontinuation ot enalapril and/or diuretic therapy In such patients, renal (unction should be monitored during the first lew weeks ol therapy Some hypertensive patients with no apparent preexisting renal vascular disease have developed increases in blood urea and serum creatimne, usually minor and transient, especially when VASOTEC has been given concomitantly with a diuretic This is more likely to occur in patients with preexisting renal impairment Dosage reduction ol VASOTEC and/oi discontinuation ol the diuretic may be required Evaluation of tin hypertensive patient should always Include assessment of renal kmctton. (See DOSAGE AND ADMINISTRATION in complete Prescribing Information ) Hyperlalemta Elevated serum potassium (greater than 5 7 mEq/L) was observed in approximately 1% ot hypertensive patients in clinical trials In most cases these were isolated values which resolved despite continued therapy Hyperkatemia was a cause of discontinuation of therapy in 0 28% ot hypertensive patients Risk factors lor the development ol hyperkatemia may include renal insufficiency diabetes mellilus, and the concomitant use ol potassium-sparing diuretics, potassium supplements, and/or potassium-containing sail substitutes, which should be used cautiously, if at all, with VASOTEC (See Drug Interactions) Surgery/Anesthesia In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II lormation secondary to compensatory renin release If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion Information lor Patients Angioedema Angioedema. including laryngeal edema, may occur especially loJIowing the first dose of enalapril Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted wrlh the prescribing physician Hypotension Patients should be cautioned to report lightheadedness especially during the first tew days of therapy If actual syncope occurs, the patients should be told lo discontinue the drug until they have consulted with the prescribing physician All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive tall in blood pressure because ot reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a lall in blood pressure, patients should be advised to consult with the physician Hyperkalemia Patients should be told not lo use salt substitutes containing potassium without consulting their physician Neutropenia Patients should be told lo report promptly any indication of infection (e g , sore throat, levef) which may be a sign of neutropenia. NOTE As with many other drugs, certain advice lo patients being treated with enatapril is warranted This information is intended lo aid in the safe and effective use ol this medication It is not a disclosure of all possible adverse or intended effects Drug Interactions Hypotension Patients on Diuretic Therapy Patients on diuretics and especially those in whom diuretic therapy was recently instituted may occasionally experience an excessive reduction of Wood pressure aftet initiation of therapy with enabpnl The possibility ol hypotensrve effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake pnor to initiation of treatment with enabpnl tl it is necessary to continue the diuretic, provide medical supervision lor at least one hour after the initial dose (See WARNINGS ana DOSAGE AND ADMINISTRATrON in complete Prescribing Information) Agents Causing ftenm Release. The antihypertensive effect ol VASOTEC is augmented by andhypertensive agents that cause renin release (e.g_, diuretics). Other Cardiovascular Agents. VASOTEC has been used concomitantly with beta-adrenergicblocking agents, methykJopa, nitrates, calcium-blocking agents, hydralazme, and prazosin without evidence ol clinically significant adverse interactions Agents Increasing Serum Potassium VASOTEC* (Enalapril Maleate, MSD) may attenuate potassium loss caused by thiazide-type diuretics Potassium-spanng diuretics (e g , spironolactone, tnamterene, or amikxide), potassium supplements, or potassium-containing salt substitutes may toad to significant increases in serum potassium Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium Pregnancy-Category C There was no fetotoxiaty or teratogenicity in rats treated with up to 200 mg/iig/day of enalapril (333 times the maximum human dose) Fetotoxiaty, expressed as a decrease in average fetal weight, occurred in rats given 1200 mg/kg/day ol enalapril but did not occur when these animals were supplemented with saline Enalapril was not leratogenic in rabbits However, maternal and fetal toxicity occurred in some rabbits at doses of 1 mg/kg/day or more Saline supplementation prevented the maternal and fetal toxicity seen at doses of 3 and 10 mg/kg/day but not at 30 mg/kg/day (50 times the maximum human dose) There are no adequate and well-controlled studies in pregnant women VASOTEC should be used during pregnancy only it the potential benefit lustities the potental risk to the fetus Nursing Mothers It is not known whether this drug is secreted in human milk Because many drugs are secreted in human milk, caution should be exercised when VASOTEC is given to a nursing mother Pedtatiic Use Safety and effectiveness in children have not been established Adverse Reactions: VASOTEC has been evaluated tor saletyin more than 10,000 patients, including over 1000 patients treated for one year or more VASOTEC has been found to be generally well tolerated in controlled clinical trials involving 2677 patients The most frequent clinical adverse experiences in controlled trials were headache (4 8%), dizziness (4 6%), and fatigue (2 8%) For the most part, adverse experiences were mild and transient in nature Discontinuation of therapy was required in 6 0% ol patients In clinical trials, the overall Irequency of adverse experiences was not related to total daily dosage within the range ol 10 to 40 mg-The overall percentage of patients treated with VASOTEC reporting adverse experiences was comparable to placebo Other adverse experiences occunmg in greater than 1% ol patients treated with VASOTEC in controlled clinical trials were diarrhea (16%), rash (15%), hypotension (14%), cough (13%), nausea (13%), and orthoslalic effects (13%) Clinical adverse experiences occurnng since the drug was marketed or in 0 5 lo 10% ot patients in the controlled trials are listed below and, within each category are in order ot decreasing severity Cardiovascular Myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see WARNINGS, Hypotension), syncope, orlhostatic hypotension, palpitations, chest pain Gastrointestinal System Ileus, pancreatitis, hepatitis or cholestatic laundice, abdominal pain, vomiting, dyspepsia, constipation Nervous System/Psychiatric Depression, contusion, somnolence, insomnia, nervousness, paresthesia. Renal Renal failure, oliguria, renal dysfunction (See PRECAUTIONS and DOSAGE AND ADMIN-ISTRATION ) Respiratory Bronchospasm, dyspnea, rhinorrhea. Other Muscle cramps, hyperhidrosis, impotence, pruritus, asthenia, photosensilrvity alopecia, flushing, taste alteration, tinnitus, glossitis A symptom complex has been reported which may include lever, myalgia, and arthralgia, an elevated erythrocyte sedimentation rate may be present Rash or other deimalologic manifestations may occur These symptoms have disappeared after discontinuation of therapy Angioedema Angioedema has been reported in patients receiving VASOTEC (0 2%) Angioedema associated with laryngeal edema may be fatal If angioedema ol the face, extremities, lips, tongue, glottis, and/or larynx occurs, treatment with VASOTEC should be discontinued and appropriate therapy instituted immediately (See WARNINGS) Hypotension Combining the results ol clinical trials in patients with hypertension or congestive heart failure, hypotension (including postural hypotension and other orthostatic effects) was reported in 2 3% of patients following the initial dose of enalapril or during extended therapy In the hypertensive patients, hypotension occurred in 0 9% and syncope occurred in 0 5% of patients Hypotension or syncope was a cause for discontinuation ol therapy in 01% ot hypertensive patients (See WARNINGS) Clinical Laboratory lest Findings Serum Electiolytes Hyperkalemia (see PRECAUTIONS), hyponatremia. Creatimne, Blood Urea Nitrogen In controlled clinical trials, minor increases in blood urea nitrogen and serum creatimne, reversible upon discontinuation of therapy, were observed in about 02% ot patents with essential hypertension treated with VASOTEC alone Increases are more likety to occur in patients receiving concomitant diuretics or in patients with renal artery stenosis (See PRECAUTIONS) Hemoglobin and Hematocnt Small decreases in hemoglobin and hematocnl (mean decreases of approximately 0 3 g% and 10 vol%, respectively) occur frequently in hypertensive patients treated with VASOTEC but are rarely ol clinical importance unless another cause ol anemia coexists In clinical trials, less than 01% ot patients discontinued therapy due to anemia Other (Causal Relationship Unknown) In rrarketing experience, rare cases of neutropenia, thrombocytopenia, and bone marrow depression have been reported Liver Function lests Elevations ollrver enzymes and/or serum bilirubin have occurred Dosage and Administration: In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of VASOTEC The diuretic should, if possible, be discontinued lor two lo three days before beginning therapy with VASOTEC lo reduce the likelihood of hypotension (See WARNINGS) If the patient's blood pressure is not controlled with VASOTEC alone, diuretic therapy may be resumed If the diuretic cannot be discontinued, an initial dose ol 2 5 mg (break the 5-mg tablet) should be used under medical supervision tor at least one hour to determine whether excess hypotension will occur (See WARNINGS and PRECAUTIONS, Drug Interactions) The recommended initial dose in patients not on diuretics is 5 mg once a day Dosage should be adjusted according lo Wood pressure response The usual dosage range is 10 to 40 mg per day administered in a single dose or in two divided doses In some patients treated once daily the antihypertensrve effect may diminish toward the end of the dosing interval In such patients, an increase in dosage or twice-daily administration should be considered II Wood pressure is not controlled with VASOTEC atone, a diuretic may be added Concomitant administration ol VASOTEC with potassium supplements, potassium salt subsliMes, or potassium-spanng diuretics may lead to increases of serum potassium (see PRECAU-TIONS) Dosage Adjustment m Renal Impairment The usual dose of enalapril is recommended lor patients with a creatinine clearance >30 rnLTmin (serum creatinine of up to approximately 3 mg/dt) For patients with creatinine clearance <30 mt/nun (serum creatinine » 3 rng/dt), the first dose is 2 5 mg once daily The dosage may be titrated upward until blood pressure is controlled or to a maximum ol 40 mg daf ly For oSalyas patents, the initial dose and the dose on dialysis days is 2 5 mg/day Dosage on nondialysis days should be adiusted depending on blood pressure response 
